




# PHARMACEUTICAL 2020

Avalo Therapeutics Inc.  
Rank 185 of 358





# PHARMACEUTICAL 2020

Avalo Therapeutics Inc.  
Rank 185 of 358



The relative strengths and weaknesses of Avalo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avalo Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Avalo Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 78%, being 42% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	17,724
Cost of Goods Sold	-567
Intangible Assets	16,835
Liabilities, Current	12,160
Liabilities, Non-Current	1,112
Other Assets	1,550
Other Compr. Net Income	0
Other Expenses	1,847
Other Liabilities	1,841
Other Net Income	345
Other Revenues	6,750
Property and Equipment	0
Research and Development	11,764
Selling, General and Administrative Expense	10,123

Output Variable	Value in 1000 USD
Assets	36,109
Liabilities	15,113
Expenses	23,168
Revenues	6,750
Stockholders Equity	20,996
Net Income	-16,073
Comprehensive Net Income	-16,073
Economic Capital Ratio	78%